Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet

Trial Profile

Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Trabectedin (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms RETRO-ROC
  • Most Recent Events

    • 10 Aug 2016 Planned End Date changed from 1 Jun 2015 to 1 Dec 2016.
    • 10 Aug 2016 Planned primary completion date changed from 1 May 2015 to 1 Dec 2016.
    • 10 Aug 2016 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top